Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0780 and Rosuvastatin PK Interaction Study
NCT05787002Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of laroprovstat in dyslipidemia (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from 0 to infinity (AUCinf) of Rosuvastatin, Area under the plasma concentration-curve from 0 to the last quantifiable concentration of Rosuvastatin and 8 more. Started Mar 2023; status: completed.
02
Drugs
laroprovstat
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT05787002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787002.